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The usefulness of NICE guidance
in practice: Different perspectives








Objectives: The UK National Institute for Health and Clinical Excellence (NICE) has been
widely hailed as an international leader in health technology assessment. The objectives
of its guidance are to ensure uniformity in healthcare provision, and promote a systematic
and accountable way to allocate resources. However, research relating to the
implementation of guidance is limited, and little is known about how it influences decision
making at the consultation level or how useful it is to individual patients.
Methods: In-depth interviews were undertaken with professionals involved in healthcare
provision at the community level, and with clinical professionals and patients providing or
receiving care for morbid obesity and breast cancer (n = 52).
Results: Although NICE guidance was generally well-regarded, in practice it was of more
importance and usefulness to managerial than clinical professionals. Clinicians used a
patchy approach to implementation depending on whether recommendations accorded
with their personal interpretation of the evidence available, and whether funding was
available locally. Many patients had not heard of NICE, and clinical professionals did not
alert them to its existence. Even where patients knew about relevant guidance, they were
rarely able to use it to assert their right to treatment.
Conclusions: These findings challenge the perception that NICE guidance results in
consistent and accountable decision making, and the limited accessibility and usefulness
of guidance to patients suggests more information and support is needed at the point of
provision if these objectives are to be achieved.
Keywords: NICE, Rationing, Guideline implementation, Doctor–patient relationships,
Patient knowledge




The past 2 decades have seen an international proliferation
in the establishment of bodies to assess the effectiveness of
healthcare technologies, and the UK National Institute of
Health and Clinical Excellence (NICE) celebrated its tenth
birthday last year (13). NICE is a national, autonomous body,
and, although funded as part of the National Health Service
(NHS), operates independently from governmental control.
NICE has the role of explicitly assessing the effectiveness and
cost-effectiveness of new and (increasingly) existing health-
care technologies, along with drawing up expert guidelines
for the treatment of particular health conditions, and issuing
recommendations for the use of selected clinical and public
health interventions (14). NICE issues recommendations to
NHS bodies working at the meso level of healthcare provision
throughout England and Wales, with particular importance
being attached to the implementation of Technology Ap-
praisal Guidance (TAGs), which is mandatory within three
months of issue.
The establishment of NICE had two main objectives—
to establish a more systematic and accountable way to set
healthcare priorities, and to reduce area variation in the avail-
ability of healthcare (15). It has been hailed as a success at
both a national and international level, and has repeatedly
been acclaimed as a beacon model for health technology
assessment (HTA) agencies around the world (9;21). NICE
is particularly praised for its centralized approach to pro-
ducing and disseminating guidance, its clear integration of
cost-effectiveness into technology appraisals, and, latterly,
its attempts to explicitly integrate social value judgments
into the decision-making process through the establishment
of a “Citizen’s Council” (9;15;21). Nevertheless, NICE has
been a controversial body since its inception, and particular
pieces of guidance come under frequent scrutiny in the pop-
ular and clinical media (13). In the academic literature, the
NICE decision-making process has met several criticisms,
including its heavy reliance on cost-utility analysis (4), its
failure to take account of the opportunity costs of imple-
menting guidance (1), and the lack of evidence-base for the
cost-effectiveness threshold commonly used (11).
Research about the use of NICE guidance in practice
remains limited. Evidence that does exist is mainly based on
large-scale audits of drug and intervention usage, and sug-
gests a steady overall increase in adherence although signif-
icant regional disparities in implementation remain (18–20).
However, two of these studies are based solely on a con-
sideration of guidance relating to cancer drugs, and detailed
studies of the implementation of particular NICE recommen-
dations suggest significant regional disparities in implemen-
tation persist (10;12)
Numerous studies in the United Kingdom and elsewhere
have shown that the implementation of HTA guidance is
heavily dependent on both its cost and the local availability
of funding (6;7;20). Additionally, clinicians report that im-
plementation is problematic where it conflicts with individual
patient advocacy (2;6), and it is unknown to what extent it
is actually used in decision making at the consultation level.
Little is known about the importance and usefulness of HTA
guidance to individual patients, and Coulter (3) has argued
that patients are likely to be poorly informed and resourced
when it comes to using NICE guidance in practice.
This study reports findings from a qualitative study
where the views of health service managers, public health
professionals, clinicians, and patients were sought with re-
gard to both how they regarded the role of NICE in theory,
and how useful such guidance was to them in practice.
METHODOLOGY
This study was part of a broader research project investigating
patients’ and healthcare providers’ experiences of, and pref-
erences for, implicit and explicit healthcare rationing. The
research design was structured around an initial interview
study with professionals working at the community level of
provision, and was followed by two case studies relating to
the experiences of patients and clinical professionals of using
or providing treatments for morbid obesity and breast cancer.
Approval was obtained from relevant NHS ethics committees
before fieldwork being undertaken.
For the community study, contributors were recruited
using a snowballing approach based on the recommendation
of key informants identified during the set up of the research.
Views were sought regarding treatment areas that were
currently the subject of contentious priority setting issues,
and the selection of the two clinical case studies was based
on these data. Several different professionals involved in
the delivery of morbid obesity and breast cancer care were
interviewed, including clinicians, specialist nurses, and
allied healthcare professionals, and these professionals
facilitated access to patients. Data were collected through
in-depth interviews, which were audio-recorded and fol-
lowed a brief topic guide (Table 1), which was developed on
the basis of a literature review and amended as interviews
progressed so that emergent themes could be followed up.
Data analysis was carried out according to the methods of
constant comparison (8), and data collection and analysis
were carried out iteratively to ensure that emerging themes
of interest could be followed up. Sampling was on-going
until a full exploration of the themes relevant to the core
research objective was achieved. A more detailed description
of recruitment processes and data collection and analysis is
reported elsewhere (16).
This study reports findings from those parts of interviews
where informants were talking about their views regarding
the role and status of NICE guidance and how it was used in
practice, and findings related to other issues included in the
interviews have been reported separately (16;17).
RESULTS
Two public health consultants, two primary care physi-
cians, and seven healthcare managers were recruited to the
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Table 1. Relevant Extracts from Interview Topic Guides
Managerial informants Clinical professionals Patients
To what extent do you think government
health policies impact on your daily
practice? Encourage expansion and
follow up on resource allocation points.
What are the criteria for referral into this
service/to have [treatment]? How far are
resource issues influential in these
decisions?
Were you offered any other treatments at
various points? Would you have wanted
to know if other treatments were
available?
Is your work influenced by NICE
recommendations? What do you think
the role of NICE is – follow up on
consistency and transparency in
resource allocation and ask for opinions.
How do you decide who is a suitable
candidate for [particular treatment]?
Probe use of external guidance and
opinions relating to the role of NICE, etc.
Was there ever an occasion when you were
asking for more treatments than they
were being given? What was your
reaction to this? (Probe
acceptance/protest/payment) Probe any
knowledge of NICE guidance / area
variation in care.
Is the move toward being more open about
resource allocation decisions a good
one? Why/why not?
If services are not funded on the NHS,
should patients still be told that the
service is available but not funded, or is
it better for them to not know?
Do you think the clinicians involved have
offered you all the treatments that are
available? Would you have liked more
information?
Who is most important in guiding your
allocation decisions, e.g., central
authorities, SHA, Trust managers?
Do patients ‘know their rights’ in terms of
NICE guidance, etc.?
NICE, National Institute for Health and Clinical Excellence.













2 0 0 2
Funding
managers
7 0 0 7
Clinical
professionals
2 5 5 12
Patients 0 13 18 31
Total 11 18 23 52
community study. In addition, thirty-one patients and twelve
clinical professionals involved in receiving or providing sec-
ondary care treatment for morbid obesity or breast cancer
care were interviewed (see Table 2). The data revealed dif-
ferences in how managerial professionals (under which we
have categorized both public health professionals and fund-
ing managers), clinical professionals, and patients viewed
NICE guidance, and their experience of using it in practice
also varied.
Views and Experiences of Managerial
Informants
Nearly all managerial informants were involved in ensur-
ing local funding bodies fulfilled their legal obligations with
regard to the implementation of NICE TAGs, and saw this
guidance as of the utmost priority in the organization of local
healthcare provision.
If it’s a NICE drug . . . we’ll always have the money - we just
have to take it from somewhere else. (P7, funding manager)
Most managers had a positive view of NICE guidance, and
five applauded its explicit and systematic approach to deci-
sion making.
In the past the NHS would have made rationing decisions
based on arbitrary criteria, whereas now it’s actually saying,
“we’ve looked at the evidence and the cost per QALY.” (P5,
funding manager)
However, managerial informants also acknowledged several
problems with NICE guidance. All but one criticized the lack
of consideration of affordability, which sometimes resulted
in the displacement of local priorities or the persistence of
area variation in access to care.
Often it feels like NICE is committing NHS funding but not
helping with the problem of inadequate funding. (P2, public
health professional)
Additionally, two were suspicious that NICE guidance was
sometimes subject to influence by bodies with vested in-
terests, such as the government or the pharmaceutical
industry.
What the health service has to do is make resource allocation
decisions, which means choosing between do we do A or do
we do B? NICE doesn’t do that—NICE says, “with all these
drug companies breathing down our necks . . . manipulating
the public and threatening to sue us, should we say yes or no
to this drug for this indication?” And they almost always say
yes. (P20, public health professional)
Experiences in Practice
Despite their concerns around affordability, NICE guidance
was often useful to managers, and three commented that it
relieved their burden of decision making when it came to
making judgments between competing claims on resources,
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with the implication that it could help them to control the
behavior of clinical professionals.
You’d think evidence-based prescribing would make life eas-
ier, but it ends up like a convention of religious zealots quot-
ing different passages of the Bible at each other . . . the NICE
guidelines make it good because it’s something written in
stone . . . you’ve got a piece of paper that says . . . “we pay
for this and we don’t pay for that.” (P3, funding manager)
Views and Experiences of Clinical
Professionals
Few of the professionals interviewed were critical of the
idea of NICE in theory, and the two primary care physi-
cians particularly applauded the notion of evidence-based
decision making, and ensuring patients had sufficient infor-
mation about their entitlement to healthcare.
I think its [guidance] healthy in that it encourages patients
and doctors to have an understanding about what consti-
tutes a good standard of care for particular conditions. (P4,
primary care physician)
However, two clinicians believed that NICE guidance was
not always a true reflection of the available evidence, and one
believed this was linked to pressure from particular interest
groups.
I don’t trust in the [NICE] process, because I can see what I
think is undue pressure from the pharmaceutical companies,
and undue pressure from the politicians. (P17, primary care
physician)
Where professionals did not trust the reliability of NICE
guidance, or simply did not agree with conclusions drawn, it
was less likely to be implemented.
I think where we [GPs] perceive that NICE guidance has
come up with politically correct statements, I think we are
pretty skeptical and probably ignore it. For instance . . . pre-
scribing of obesity medications . . . I don’t think that’s the
right solution to those problems. (P17, primary care physi-
cian)
Experiences in Practice
Both primary care physicians interviewed found NICE
guidance useful to assist their decision making in practice.
I’m not in a position as an individual to have the time to go
into depth on all the research on a particular drug – and I cer-
tainly haven’t got the skills required to make a balanced judg-
ment on overall risk-benefit [and] cost-effectiveness. (P17,
primary care physician)
However, guidance was of limited usefulness to those
working in secondary care. For those working in breast can-
cer, guidance was not issued quickly enough to assist deci-
sion making on the latest drugs available, and, for morbid
obesity professionals, local funding bodies were simply un-
able to provide the service recommended by NICE, mean-
ing that additional local prioritization criteria needed to be
applied.
Research is moving much faster than our ability to subse-
quently have bureaucratic organizations like NICE then col-
late and oversee all the data. (P14, specialist breast cancer
clinician)
I’ve got somebody who it [NICE criteria] fits perfectly . . .
her body mass index is fine, her age is fine, she’s got two
comorbidities. . . . No funding . . . they [PCT] just haven’t
got the money. (P13, specialist obesity nurse)
Several professionals noted that the existence of NICE guid-
ance can make it more difficult for them to resist patients’
demands for treatments they believe are inappropriate, and
two (P16, P17) commented that it can sometimes result in
overtreatment.
Sometimes you end up in the ridiculous situation of actu-
ally feeling obliged to use a treatment because it’s NICE
approved, even if you don’t think it’s the best thing to do.
(P16, specialist breast cancer clinician)
However, in other circumstances the availability of guidance
made it easier for informants to ration treatments.
For us it’s [NICE guidance] a good defense . . . this week
I’ve had somebody . . . she clearly isn’t fat enough for weight
loss surgery, [but] rather than being cruel . . . I can say well
“you don’t follow the national guidelines.” (P13, specialist
obesity nurse)
Only one clinician (P16) talked about NICE in terms of a
rationing body that constrained her autonomy. However, she
commented that she had normally been able to find ways
around rationing decisions she disagreed with, and later sug-
gested that guidance was sometimes useful to help her insist
to managers that particular treatments are funded.
At least if things get NICE approval then we know we don’t
have to fight to use the treatment. (P16, specialist breast
cancer clinician)
The Views of Patients
Although all thirty-one patient informants were aware that
the health service faced resource shortages, and more than
two-thirds were aware that their own treatment had been
subject to rationing, informants rarely commented on NICE
without the prompting of the researcher, and six explicitly
confirmed that they had never heard of the organization.
I: Have you ever heard on the media anything about NICE,
the National Institute of Clinical Excellence?
Patient 17: Who?
Many of those who said they had heard of NICE either did
not know what it was, or misunderstood its role and confused
it with that of the drug licensing body.
I: Have you ever heard of the National Institute of Clinical
Excellence?
Patient 24: NICE? Yes I have . . . on TV and everything . . .
isn’t it they test the drug and that’s when people go on trials?
This widespread lack of knowledge about NICE contradicted
the expectations of nearly all managerial informants, and one
clinician.
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I: Have patients generally heard of things like NICE?
P14 (specialist clinician): They have . . . of course they’re
aware, the whole country’s aware.
It was only clear in six interviews that patients under-
stood the role and function of NICE, and three of these in-
formants worked for the health service themselves. These
informants expressed mixed feelings with regard to the ac-
ceptability of guidance, and informants had deep-rooted con-
cerns about the potential sacrifice of individual benefits in
favor of societal ones.
I feel in a bit of a state of conflict about NICE . . . somebody
needs to take responsibility [for rationing] . . . but where they
make a decision about, “well this drug only helps a very tiny
percentage of people . . . and therefore should we be funding
it?” . . . It almost pulls into question the value of individuals’
lives, and who has a right to place a value on that? (Patient
27)
Experiences in Practice
It was clear that NICE guidance was of no practical use to
those patients who did not know it existed, or had insufficient
information about how to access it. They were unlikely to
be alerted to this information by clinicians, who seemed
concerned this would result in demands for treatments they
could not then provide, and none of those with morbid obesity
had been directly alerted to relevant NICE guidance.
If they went to the NICE guidelines they’d say “well hold on,
NICE says that I should be able to have it [weight reduc-
tion surgery]” . . . [but] we haven’t got the funding.” (P6,
specialist obesity clinician)
However, three patients (Pa3, Pa5, Pa9) had researched NICE
guidance themselves before their initial consultation with
their GP, and one (Pa30) had been indirectly alerted to its
existence after seeing a copy of a communication between
her GP and the local PCT. However, none of these patients
had been able to use NICE guidance to successfully argue
they were entitled to treatment.
It [NICE guidance] made no difference. (Pa30)
DISCUSSION
These data show that the views of professionals and patients
were not particularly discordant when it came to theoretical
views about NICE. However, in practice, recommendations
were of more importance and usefulness to professionals
working in managerial rather than clinical roles, and guid-
ance was generally of little consequence to patients. Manage-
rial informants saw the implementation of TAGs as crucial
and routinely displaced other priorities to fund them, even
where they personally believed opportunity costs of imple-
mentation were unjustified. However, clinical professionals
applied a patchy approach to the implementation of NICE
guidance, depending on whether it fitted with their personal
opinion and interpretation of the evidence available, as well
as whether funding was available locally to provide care. It
was notable that both managerial and clinical professionals
regarded NICE guidance as a means to exert power over the
other group on occasion, and theoretical views of the use-
fulness of guidance and the way it was used in practice did
not always accord. For patients, guidance was of limited use-
fulness because several did not know that relevant guidance
existed, and, even those who had used guidance to establish
their eligibility for care were rarely able to assert their right
to treatment.
The findings suggest that NICE guidance does not al-
ways fulfill its main objectives. The study provides evidence
to support previous findings that regional variations in care
persist because local funding is not always available to pro-
vide the care recommended by NICE (10;12). Additionally,
several managers in this study commented that even where
funding is made available, the pressure on resources means
other service developments have to be abandoned, which
would presumably result in different regional disparities. The
findings from this study also provide some empirical backing
to Coulter’s (3) view that patients need further information
about NICE guidance at the point of treatment if the con-
cept of explicit rationing is to be fully embraced. However,
the benefits of such a fully explicit approach need to be
weighed against the implications of the finding that theoret-
ical views on the acceptability of rationing are superseded
by anger and distress when individual treatment is withheld
(16).
Using qualitative techniques meant the researcher was
able to elicit informants’ often-conflicting opinions around
the acceptability of NICE guidance, and could probe to what
extent it was useful to these individuals in practice. Addition-
ally, it provided scope to sensitively explore whether patients
were aware of NICE guidance, and what they understood
about its role and importance. However, such in-depth tech-
niques inevitably affected the scope of the research, and,
although the use of two clinical case studies was useful to
provide some consistency by which to compare individual
accounts, the extent to which the views and experiences of
informants are typical of professionals and patients more
broadly is unknown. A useful area for future research would
be to explore the relevance of these findings to other clini-
cal settings, with particular emphasis on further investigation
of patients’ views on the role of NICE, and the reasons for
the patchy implementation of recommendations by clinical
professionals. Additionally, it would be interesting to follow
up the finding that guidance was seen as more important to
managers than clinicians, and investigate whether healthcare
professionals view NICE guidance as a mechanism to pro-
mote clinical excellence or merely as a tool to facilitate cost
containment.
However, perhaps the most important priority for fur-
ther inquiry is to find out how NICE guidance can be made
more accessible to patients at the point of accessing care, to
avoid the risk of it becoming simply another tool in the power
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struggle between clinicians and managers when it comes to
resource allocation. An understanding of how patients can
understand and exert their rights to NHS care is also relevant
to the effective implementation of the newly launched NHS
constitution (5), where it seems likely that the same barri-
ers to the accessibility and usefulness of information will
exist.
CONCLUSION
This study showed that, at least in these two clinical areas,
different stakeholders had widely diverging opinions on the
status and importance of NICE guidance, and patients often
either did not know about the existence of relevant guid-
ance, or were unable to use it to access appropriate care. It
is important to understand how guidance can be made more
accessible and useful to patients at the point of need if ex-
plicit rationing is to be embraced, or at least to avoid social
inequality in access to information about healthcare decision
making, and potentially healthcare.
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